UNLIMITED TURBO LONG - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:02 2024-05-15 pm EDT | ||
| 7.825 EUR | +35.50% |
|
| Current month | +2.06% | ||
| 1 month | +20.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 7.825 | +35.50% |
| 24-05-14 | 5.775 | +0.52% |
| 24-05-13 | 5.745 | -13.80% |
| 24-05-10 | 6.665 | -11.19% |
| 24-05-09 | 7.505 | -3.35% |
Real-time Euronext Paris
Last update May 15, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| OP8NB | |
| ISIN | FRBNPP06JSY1 |
| Date issued | 2024-03-04 |
| Strike | 694.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.02 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.19 € |
|---|---|
| Lowest since issue | 3.03 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- OP8NB Certificat
